Author of

• 20164

  +

  P1.15 - SCLC/Neuroendocrine Tumors (ID 701)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: SCLC/Neuroendocrine Tumors
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 22797

    +

    P1.15-012 - Clinical Prognostic Factors of Elderly Patients with Extensive Stage Small Cell Lung Cancer in Korea (ID 9674)

    09:30 - 09:30  |  Presenting Author(s): Jung Sun Kim
    • Abstract
    • Slides

    Background:
    SCLC represents 15% of all lung cancers and is one of the most aggressive types with rapid progression. Because of this, two thirds of patients are diagnosed with ED. The ED-SCLC is highly sensitive to chemotherapy. However, many patients are diagnosed in ages 65 and older. This retrospective study was designed to examine factors associated with chemotherapy administration among elderly patients with SCLC and to quantify the survival benefit.
    
    Method:
    Between Jan 1995 and Dec 2015, we analyzed 88 cases of elderly patients with ED-SCLC who treated chemotherapy in Korea University Medical Center.
    
    Result:
    A total of 88 patients were diagnosed ED- SCLC at the age 65 and older. Median age is 71 years old (range 65-83). Most of cases were male (82%) and 16 patients were female (18%). The most common chemotherapy regimens included etoposide combined with platinum. Median overall survival was 8.65 months. In multivariate analysis, ECOG PS <2, SCS <9, administration > 4 cycles of 1[st] line chemotherapy and treatment-free interval (TFI) > 3 months were defined as a favorable prognostic factors. Figure 1

    	Univariate			Multivariate
    	HR	95% CI	p value	HR	95% CI	p value
    ECOG PS 0,1 ≥2	0.34 1	0.18-0.67	0.002	0.60 1	0.31-1.16	0.13
    SCS <9 ≥9	0.42 1	0.26-0.66	< 0.001	0.52 1	0.32-0.82	0.005
    1st line chemotheraly ≤4cycles >4cycles	1 0.44	0.28-0.70	0.004	1 0.44	0.27-0.72	0.005
    Response to 1st line Tx. CR,PR SD,PD	0.49 1	0.31-0.79	0.003	0.45 1	0.28-0.72	0.001
    TFI* (months) ≤3 >3	1 0.36	0.17-0.76	0.007	1 0.37	0.17-0.78	0.01

    
    
    
    
    Conclusion:
    Even an elderly patient with ED- SCLC who has lower SCS< 9 and good ECOG PS <2 should consider first line chemotherapy more than 4cycles.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.